Cargando…
Alectinib-Induced Pleural and Pericardial Effusions in ALK-Positive NSCLC
Alectinib is the first-line targeted treatment for advanced ALK-positive non-small-cell lung cancer. Although it has a relatively mild toxicity profile, adverse events (AEs) do occur. We present a case of alectinib-induced bilateral pleural effusions and pericardial effusion that has not previously...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525301/ https://www.ncbi.nlm.nih.gov/pubmed/34720935 http://dx.doi.org/10.1159/000518081 |